Bisphosphonate-associated atypical subtrochanteric femur fracture

Ely A. Wolin, Kevin P. Banks, Penny J. Vroman

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Bisphosphonates help prevent progressive bone mineralization loss and subsequent osteoporotic fractures. However, long-term bisphosphonate therapy paradoxically increases the risk of a unique injury called an atypical subtrochanteric femur fracture. Despite this, the benefits of bisphosphonates outweigh the risks, because far more pathologic fractures are prevented than induced. The early identification of atypical subtrochanteric femur fractures is important as there is high associated morbidity and mortality. We describe a case of a 76-y-old woman with a completed bisphosphonate-associated atypical subtrochanteric femur fracture.

Original languageEnglish (US)
Pages (from-to)72-73
Number of pages2
JournalJournal of Nuclear Medicine Technology
Issue number1
StatePublished - 2015
Externally publishedYes


  • Atypical subtrochanteric femoral fracture
  • Bisphosphonate
  • Osteoporosis

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Bisphosphonate-associated atypical subtrochanteric femur fracture'. Together they form a unique fingerprint.

Cite this